Aptevo Therapeutics Inc. (APVO) Analysts See $-0.32 EPS; Solitario Exploration & Royalty Has 1.5 Sentiment

February 25, 2018 - By Marguerite Chambers

Solitario Zinc Corp., an exploration and royalty company, engages in the acquisition, exploration, and development of precious and base metal properties in Peru, Brazil, and Mexico. The company has market cap of $29.46 million. The firm primarily explores for gold, silver, platinum, palladium, copper, lead, and zinc deposits. It currently has negative earnings. It primarily holds interests in the Bongará project comprising 16 concessions that covers an area of 12,600 hectares located in the Department of Amazonas, northern Peru; Chambara zinc property located in northern Peru; Newmont Alliance and the La Promesa project located in Peru.

Analysts expect Aptevo Therapeutics Inc. (NASDAQ:APVO) to report $-0.32 EPS on March, 30.They anticipate $0.33 EPS change or 3,300.00% from last quarter’s $0.01 EPS. After having $0.14 EPS previously, Aptevo Therapeutics Inc.’s analysts see -328.57% EPS growth. The stock increased 0.31% or $0.01 during the last trading session, reaching $3.28. About 51,523 shares traded. Aptevo Therapeutics Inc. (NASDAQ:APVO) has 0.00% since February 25, 2017 and is . It has underperformed by 16.70% the S&P500.

Aptevo Therapeutics Inc., a biotechnology company, engages in the discovery, development, commercialization, and sale of novel oncology and hematology therapeutics in the United States. The company has market cap of $70.33 million. The Company’s marketed products include IXINITY, which is indicated in adults and children 12 years of age and older with hemophilia B for control and prevention of bleeding episodes, and management of bleeding during operations; and WinRho SDF for the treatment of autoimmune platelet disorders, as well as for the treatment of hemolytic disease of the newborn. It has a 38.59 P/E ratio. The company's marketed products also comprise HepaGam B used for the prevention of hepatitis-B recurrence following liver transplantation in HBsAg-positive liver transplant patients, and for the treatment following exposure to hepatitis-B; and VARIZIG for use in treating following exposure to varicella zoster virus, which causes chickenpox in high-risk individuals.

Fruth Investment Management holds 0.06% of its portfolio in Solitario Zinc Corp. for 203,000 shares. Bruce & Co. Inc. owns 254,040 shares or 0.04% of their US portfolio. Moreover, Agf Investments Inc. has 0% invested in the company for 111,630 shares. The Minnesota-based Ameriprise Financial Inc has invested 0% in the stock. Banque Pictet & Cie Sa, a Switzerland-based fund reported 100,000 shares.

The stock increased 2.38% or $0.012 during the last trading session, reaching $0.504. About 115,281 shares traded or 4.37% up from the average. Solitario Zinc Corp. (XPL) has risen 63.04% since February 25, 2017 and is uptrending. It has outperformed by 46.34% the S&P500.